Arrayit Corp (ARYC) is confident that the finger stick microarray immunoassays technology will receive FDA approval. This technology, proven to be accurate by College of American Pathologists, will be the first of its kind to be utilized for clinical purposes... For accurately testing allergy symptoms.
Many shareholders have received emails stating that the plan is for the company to up-list to NASDAQ this year.
Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval. https://twitter.com/arrayit/status/1014171600051007488
Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com
focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more than 10% of the company.
In addition, the regular bid price at time of listing must be $4.00, and there must be at least three market makers for the stock.
However, a company may qualify under a closing price alternative of $3.00 or $2.00 if the company meets varying requirements.
Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360.
Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months